iRhythm’s stock price has taken a beating over the past six months, shedding 27.5% of its value and falling to $115.17 per share. This may have investors wondering how to approach the situation.

iRhythm’s second quarter results were met with a strong positive market reaction, reflecting the company’s ability to deliver both robust revenue growth and significant margin improvement. Management attributed this performance to sustained demand for the Zio ambulatory cardiac monitoring platform and effective commercial execution across cardiology, primary care, and new healthcare channels. CEO Quentin Blackford noted that the company’s operational discipline and successful integration of digi

IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.

Revenue jumped 20% while margins expanded, and the company raised full-year guidance.

Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) fell 2.8% in the afternoon session after a significant price target cut from an analyst overshadowed the company's strong quarterly earnings report.

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong second-quarter financial results that surpassed expectations and raised its full-year guidance.

iRhythm (IRTC) could benefit from stronger sales growth, wider access to the cardiac monitoring mark

IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.

Acquiring VitalConnect could unlock a $1 billion cardiac monitoring market that is only partly served by iRhythm’s existing devices.

Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 20.1% year on year to $224.2 million. The company expects the full year’s revenue to be around $885 million, close to analysts’ estimates. Its non-GAAP profit of $0.58 per share was significantly above analysts’ consensus estimates.

In early August 2026, iRhythm Holdings reported second-quarter 2026 results showing sales rising to US$224.17 million and net loss narrowing to US$0.381 million, while also increasing its full-year 2026 revenue guidance to US$880 million–US$890 million and announcing a proposed US$45.00 million securities class action settlement related to its Zio AT device disclosures. The combination of stronger operating performance, raised guidance, the planned VitalConnect acquisition and progress...

The heart monitor leader iRhythm Holdings is moving to help doctors track their patients’ health outside the clinic. It’s doing it through an acquisition.

IRhythm announced the deal alongside its Q2 financials in which its revenues rose 20.1% YoY.

Moby summary of iRhythm Technologies, Inc.'s Q2 2026 earnings call

iRhythm Holdings Inc (IRTC) delivers seventh consecutive quarter of 20%+ revenue growth, raises full-year guidance, and expands market reach with VitalConnect acquisition.

iRhythm Technologies (NASDAQ:IRTC) reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets. Revenue for the quarter ended at $2

IRHYTHM HLDGS (IRTC) delivered earnings and revenue surprises of +5,900.00% and +2.18%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical technology company iRhythm Technologies (NASDAQ:IRTC) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 20.1% year on year to $224.2 million. The company expects the full year’s revenue to be around $885 million, close to analysts’ estimates. Its non-GAAP profit of $0.58 per share was significantly above analysts’ consensus estimates.

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the ones that make you life-changing money.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns as healthcare stocks have gained 11.9% over the past six months while the S&P 500 was up 8.7%.